Cabozantinib and Pembrolizumab for the First-Line Treatment of Advanced Liver Cancer

Summary

This phase II trial studies how well cabozantinib and pembrolizumab work for the first-line treatment of patients with liver cancer who are not eligible for local therapy (i.e. advanced stage). Cabozantinib may stop the growth of tumor cells by blocking some cell surface receptors and signaling pathways inside the tumor cells. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer. Giving cabozantinib and pembrolizumab together may work better in treating patients with advanced liver cancer compared to cabozantinib or pembrolizumab alone.

Timeline

Start

2021-04-20

Primary completion

2021-12-13

Completion

2022-03-08

Outcome

Outcome not reported

Stopped (Enrollment): “Terminated due to slow accrual”

Drugs

Indications